Profile data is unavailable for this security.
About the company
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
- Revenue in USD (TTM)49.88bn
- Net income in USD7.96bn
- Incorporated1996
- Employees110.00k
- LocationNovartis AGLichtstrasse 35BASEL 4056SwitzerlandCHE
- Phone+41 613241111
- Fax+41 613247826
- Websitehttps://www.novartis.com/
More ▼
Mergers & acquisitions
| Acquired company | NOVN:SWX since announced | Transaction value |
|---|---|---|
| Cadent Therapeutics | -0.04% | 770.00m |
| Vedere Bio Inc | -0.01% | 280.00m |
Data delayed at least 15 minutes, as of May 14 2021 16:37 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | 29.24bn | 3.44bn | 53.96bn | 47.50k | 15.59 | 1.13 | 6.31 | 1.85 | 239.95 | 239.95 | 2,037.44 | 3,308.93 | 0.2485 | 1.31 | 4.15 | -- | 2.92 | 1.97 | 3.45 | 2.44 | 68.91 | 68.64 | 11.76 | 7.10 | 1.10 | 4.16 | 0.4724 | 131.22 | -2.84 | 12.09 | 749.90 | 36.22 | 22.75 | 0.00 |
| Chugai Pharmaceutical Co Ltd | 7.10bn | 1.93bn | 63.26bn | 7.56k | 32.18 | 6.89 | -- | 8.91 | 128.02 | 128.02 | 471.90 | 597.67 | 0.7089 | 1.49 | 4.03 | 102,758,300.00 | 19.23 | 12.76 | 22.42 | 15.21 | 65.54 | 57.67 | 27.13 | 19.27 | 3.86 | 483.15 | 0.00 | 46.76 | 14.68 | 9.55 | 36.29 | 28.57 | 19.44 | 25.98 |
| Bayer AG | 49.64bn | -18.03bn | 68.06bn | 99.33k | -- | 1.62 | -- | 1.37 | -15.11 | -10.07 | 41.63 | 35.21 | 0.3348 | 1.87 | 3.00 | 410,727.60 | -12.15 | -0.9407 | -15.41 | -1.20 | 53.09 | 60.72 | -36.30 | -2.48 | 0.8759 | 9.86 | 0.5521 | -- | -4.93 | -2.12 | -751.15 | -- | -0.7993 | -4.06 |
| Novartis AG (ADR) | 49.88bn | 7.96bn | 219.20bn | 110.00k | 25.59 | 3.95 | 15.25 | 4.39 | 3.48 | 3.48 | 21.80 | 22.50 | 0.4075 | 2.19 | 5.94 | 471,520.10 | 6.50 | 6.41 | 8.68 | 8.01 | 70.58 | 69.39 | 15.95 | 17.79 | 0.504 | -- | 0.4277 | 81.09 | 2.62 | -0.1838 | 13.02 | 2.84 | -5.91 | 2.98 |
| Roche Holding AG | 64.71bn | 15.86bn | 294.41bn | 101.47k | 18.37 | 7.12 | 13.52 | 4.55 | 16.52 | 16.52 | 67.43 | 42.60 | 0.6893 | 2.40 | 5.66 | 574,809.10 | 17.81 | 14.82 | 26.63 | 22.08 | 72.74 | 71.39 | 25.84 | 20.92 | 1.01 | 41.00 | 0.2633 | 66.01 | -5.11 | 3.91 | 5.91 | 10.03 | 13.84 | 2.36 |
Data as of May 15 2021. Currency figures normalised to Novartis AG's reporting currency: US Dollar USD
4.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dodge & Coxas of 31 Mar 2021 | 21.67m | 0.88% |
| PRIMECAP Management Co.as of 31 Mar 2021 | 20.54m | 0.83% |
| Loomis, Sayles & Co. LPas of 31 Dec 2020 | 20.12m | 0.82% |
| Optiver US LLCas of 31 Mar 2021 | 13.88m | 0.56% |
| Fisher Asset Management LLCas of 31 Mar 2021 | 9.66m | 0.39% |
| Franklin Mutual Advisers LLCas of 31 Mar 2021 | 8.34m | 0.34% |
| Aristotle Capital Management LLCas of 31 Dec 2020 | 7.12m | 0.29% |
| Managed Account Advisors LLCas of 31 Mar 2021 | 7.01m | 0.28% |
| Boston Partners Global Investors, Inc.as of 31 Mar 2021 | 5.86m | 0.24% |
| UBS Financial Services, Inc.as of 31 Mar 2021 | 5.02m | 0.20% |
More ▼
Data from 31 Dec 2020 - 31 Mar 2021Source: FactSet Research Systems Inc.
